M Saigi1, A McLeer-Florin2, E Pros1, E Nadal3,4, E Brambilla2, M Sanchez-Cespedes5. 1. Cancer Epigenetics and Biology Program (PEBC), Genes and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908, Barcelona, Spain. 2. Département d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble and Université Grenoble Alpes, Grenoble, France. 3. Department of Medical Oncology, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 4. OncoBell Program, Clinical Research in Solid Tumors (CReST) Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 5. Cancer Epigenetics and Biology Program (PEBC), Genes and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908, Barcelona, Spain. mscespedes@idibell.cat.
Abstract
PURPOSE: Aberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study was to characterize MET alterations in a cohort of NSCLC patients treated with surgery. METHODS AND PATIENTS: 157 NSCLCs of various histopathologies, including pulmonary sarcomatoid carcinomas (PSC), were tested for MET alterations. METex14 mutations, MET copy number alterations and the levels of MET protein were determined by Sanger sequencing, fluorescence in situ hybridization and immunohistochemistry, respectively. Concurrent alterations of other important cancer genes and immunostaining of the downstream effector, phopho-S6, were also determined. RESULTS: METex14 mutations and MET amplification were detected in seven tumors. MET genetic alterations were found predominantly in the lung adenocarcinoma (ADC) and PSC histopathologies. High levels of MET protein were found in most MET-amplified tumors, but not in all METex14-mutated tumors. Strong phopho-S6 staining was observed in about half of the MET-activated tumors. One tumor with METex14 exhibited concurrent ERBB2 amplification. CONCLUSIONS: MET activation, by either METex14 mutations or amplification, is characteristic of a subset of early stage NSCLCs and may coexist with ERBB2 amplification. This may have potential therapeutic implications. The presence of METex14 mutations was associated with low levels of MET protein, which may limit the use of total MET immunostaining as a marker for preselecting patients for MET-targeted therapies.
PURPOSE: Aberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study was to characterize MET alterations in a cohort of NSCLCpatients treated with surgery. METHODS AND PATIENTS: 157 NSCLCs of various histopathologies, including pulmonary sarcomatoid carcinomas (PSC), were tested for MET alterations. METex14 mutations, MET copy number alterations and the levels of MET protein were determined by Sanger sequencing, fluorescence in situ hybridization and immunohistochemistry, respectively. Concurrent alterations of other important cancer genes and immunostaining of the downstream effector, phopho-S6, were also determined. RESULTS: METex14 mutations and MET amplification were detected in seven tumors. MET genetic alterations were found predominantly in the lung adenocarcinoma (ADC) and PSC histopathologies. High levels of MET protein were found in most MET-amplified tumors, but not in all METex14-mutated tumors. Strong phopho-S6 staining was observed in about half of the MET-activated tumors. One tumor with METex14 exhibited concurrent ERBB2 amplification. CONCLUSIONS: MET activation, by either METex14 mutations or amplification, is characteristic of a subset of early stage NSCLCs and may coexist with ERBB2 amplification. This may have potential therapeutic implications. The presence of METex14 mutations was associated with low levels of MET protein, which may limit the use of total MET immunostaining as a marker for preselecting patients for MET-targeted therapies.
Entities:
Keywords:
MET IHC; MET amplification; MET exon 14; Non-small cell lung cancer
Authors: Jeffrey W Tyner; Luke B Fletcher; Ellen Q Wang; Wayne F Yang; Michael L Rutenberg-Schoenberg; Carol Beadling; Motomi Mori; Michael C Heinrich; Michael W Deininger; Brian J Druker; Marc M Loriaux Journal: Cancer Res Date: 2010-08-01 Impact factor: 12.701
Authors: Giorgio V Scagliotti; Silvia Novello; Joan H Schiller; Vera Hirsh; Lecia V Sequist; Jean-Charles Soria; Joachim von Pawel; Brian Schwartz; Reinhard Von Roemeling; Alan B Sandler Journal: Clin Lung Cancer Date: 2012-03-21 Impact factor: 4.785
Authors: William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Alexa B Schrock; Garrett M Frampton; James Suh; Zachary R Chalmers; Mark Rosenzweig; Rachel L Erlich; Balazs Halmos; Jonathan Goldman; Patrick Forde; Kurt Leuenberger; Nir Peled; Gregory P Kalemkerian; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Sai-Hong Ignatius Ou Journal: J Thorac Oncol Date: 2016-06-22 Impact factor: 15.609
Authors: Esther Conde; Barbara Angulo; Moying Tang; Manuel Morente; Juan Torres-Lanzas; Angel Lopez-Encuentra; Fernando Lopez-Rios; Montserrat Sanchez-Cespedes Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: Joanna H Tong; Sai F Yeung; Anthony W H Chan; Lau Y Chung; Shuk L Chau; Raymond Wai Ming Lung; Carol Y Tong; Chit Chow; Edith K Y Tin; Yau H Yu; Hui Li; Yi Pan; Wing P Chak; Calvin S H Ng; Tony S K Mok; Ka F To Journal: Clin Cancer Res Date: 2016-02-04 Impact factor: 12.531
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Joshua D Campbell; Anton Alexandrov; Jaegil Kim; Jeremiah Wala; Alice H Berger; Chandra Sekhar Pedamallu; Sachet A Shukla; Guangwu Guo; Angela N Brooks; Bradley A Murray; Marcin Imielinski; Xin Hu; Shiyun Ling; Rehan Akbani; Mara Rosenberg; Carrie Cibulskis; Aruna Ramachandran; Eric A Collisson; David J Kwiatkowski; Michael S Lawrence; John N Weinstein; Roel G W Verhaak; Catherine J Wu; Peter S Hammerman; Andrew D Cherniack; Gad Getz; Maxim N Artyomov; Robert Schreiber; Ramaswamy Govindan; Matthew Meyerson Journal: Nat Genet Date: 2016-05-09 Impact factor: 38.330
Authors: Zachary D Crees; Caleb Shearrow; Leo Lin; Jennifer Girard; Kavin Arasi; Aayush Bhoraskar; Joseph Berei; Adam Eckburg; Austin D Anderson; Christian Garcia; Ariana Munger; Sunil Palani; Thomas J Smith; Shylendra B Sreenivassappa; Connie Vitali; Odile David; Neelu Puri Journal: Ther Adv Med Oncol Date: 2020-09-14 Impact factor: 8.168